C3.ai Digital Transformation Institute Announces Research Awards for AI to Transform Cybersecurity and Secure Critical Infrastructure
24.3.2022 13:00:00 EET | Business Wire | Press release
C3.ai Digital Transformation Institute (C3.ai DTI) today announced the third round of C3.ai DTI funded advanced research awards, focused on using artificial intelligence (AI) to harden information security and secure critical infrastructure.
The Institute awarded a total of $6.5 million in cash awards to leading research scientists at University of California, Berkeley, University of Illinois at Urbana-Champaign, Carnegie Mellon, Princeton, University of Chicago, KTH Royal Institute of Technology, and MIT.
“Cybersecurity is an immediate existential issue,” said Thomas M. Siebel, chairman and CEO of C3 AI, a leading enterprise AI software provider. “We are equipping top scientists with the means to advance technology to help secure critical infrastructure.”
Twenty-four projects were awarded $100,000 to $700,000 each, for an initial period of one year:
AI Resilience: Techniques and methods to enable the development of AI algorithms that are resilient to adversarial attacks
- “High Performance Provably Robust AI Methods for Cybersecurity Tasks on Critical Infrastructure,” (Zico Kolter, Carnegie Mellon University)
- “Scalable, Secure Machine Learning in the Presence of Adversaries,” (John Kubiatowicz, University of California, Berkeley)
- “REFL: Resilient Distributed Cybersecurity Learning System,” (Bo Li, University of Illinois at Urbana-Champaign)
- “Fundamental Limits on the Robustness of Supervised Machine Learning Algorithms,” (Ben Zhao, University of Chicago)
Anomaly Detection: AI techniques, including supervised and unsupervised learning, to provide early detection of system and/or network anomalies that might be indicative of unauthorized access, denial of service, or data exfiltration
- “Continuously and Automatically Discovering and Remediating Internet-Facing Security Vulnerabilities,” (Nick Feamster, University of Chicago)
- “AI Techniques for Power Systems Under Cyberattacks,” (Javad Lavaei, University of California, Berkeley)
- “Physics-aware AI-based Approach for Cyber Intrusion Detection in Substation Automation Systems,” (Alberto Sangiovanni-Vincentelli, University of California, Berkeley)
Advanced Persistent Threats: AI techniques to detect the presence of advanced persistent threats
- “Deep-Learning Detection Algorithms for Advanced Persistent Attacks in Mixed-Autonomy Traffic: Design and Experimental Validation,” (Alex Bayen, University of California, Berkeley)
- “AI Support for Cybersecurity,” (David Wagner, University of California, Berkeley)
Securing Critical Cyber-Physical Infrastructure: AI techniques to secure critical infrastructure against cyber threats
- “Cyber Safety Cage for Networks,” (Cyrille Valentin Artho, KTH Royal Institute of Technology)
- “Security for Large-Scale Infrastructure using Probabilistic Programming,” (Nikita Borisov, University of Illinois at Urbana-Champaign)
- “A Compositional Neural Certificate Framework for Securing Critical Networked Infrastructure,” (Chuchu Fan, Massachusetts Institute of Technology)
- “Democratizing AI-Driven Security Workflows for Critical Energy Infrastructure,” (Vyas Sekar, Carnegie Mellon University)
- “Semantic Adversarial Analysis for Secure Critical Infrastructure,” (Sanjit Seshia, University of California, Berkeley)
Forensics: AI forensics and attribution techniques to identify sources of attacks
- “Causal Reasoning for Real-Time Attack Identification in Cyber-Physical Systems,” (György Dán, KTH Royal Institute of Technology)
- “Statistical Learning Theory and Graph Neural Networks for Identifying Attack Sources,” (H. Vincent Poor, Princeton University)
- “Robust and Scalable Forensics for Deep Neural Networks,” (Ben Zhao, University of Chicago)
Securing Emerging Financial Infrastructure: AI techniques to identify attacks on emerging decentralized financial and business infrastructure
- “An Intelligence Platform for Better Security in Decentralized Finance,” (Dawn Song, University of California, Berkeley)
- “Blockchain Forensics,” (Pramod Viswanath, University of Illinois at Urbana-Champaign)
Vulnerability Identification: AI techniques to identify previously unknown malware, ransomware, and zero-day vulnerabilities, enabling isolation and neutralization
- “GAN-Aided Automatic Test Case Generation,” (Giulia Fanti, Carnegie Mellon University)
- “Machine Learning for JavaScript Vulnerability Detection,” (Corina Pasareanu, Carnegie Mellon University)
Insider Threats: Change management techniques to prevent the weaponization of innocent and malicious insiders
- “Protecting Critical Infrastructures Against Evolving Insider Threats,” (Carl Gunter, University of Illinois at Urbana-Champaign)
- “Multi-Facet Rare Event Modeling of Adaptive Insider Threats,” (Jingrui He, University of Illinois at Urbana-Champaign)
- “AI-Supported Nudging for Cyber-Hygiene,” (Cedric Langbort, University of Illinois at Urbana-Champaign)
Award Criteria
C3.ai DTI selects research proposals that inspire cooperative research and advance machine learning and other AI subdisciplines. Projects are peer-reviewed on scientific merit, prior accomplishments of the principal investigator and co-principal investigators, the use of AI, machine learning, data analytics, and cloud computing in the research project, and the suitability for testing the methods at scale. Visit C3DTI.ai to learn more about the Institute’s programs, award opportunities, and selected research proposals.
About C3.ai Digital Transformation Institute
Established in March 2020 by C3 AI, Microsoft, and leading universities, the C3.ai Digital Transformation Institute is a research consortium dedicated to accelerating the benefits of artificial intelligence for business, government, and society. The Institute engages the world’s leading scientists to conduct research and train practitioners in the new Science of Digital Transformation — operating at the intersection of artificial intelligence, machine learning, cloud computing, internet of things, big data analytics, organizational behavior, public policy, and ethics.
The 10 C3.ai Digital Transformation Institute consortium member universities and laboratories are: University of California, Berkeley, University of Illinois at Urbana-Champaign, Carnegie Mellon University, KTH Royal Institute of Technology, Lawrence Berkeley National Laboratory, Massachusetts Institute of Technology, National Center for Supercomputing Applications at University of Illinois at Urbana-Champaign, Princeton University, Stanford University, and University of Chicago. Additional industry partners include AstraZeneca, Baker Hughes, and Shell.
To support the Institute, C3 AI is providing the Institute $57,250,000 in cash contributions over the initial five years of operation. In addition to cash awards, C3.ai DTI provides researchers with cloud computing, supercomputing, data, and software resources, including free, unlimited use of the C3 AI Application Platform, up to $2 million in Azure Cloud computing resources, and access to High Performance Computing (HPC) resources at the National Center for Supercomputing Applications (NCSA) at the University of Illinois at Urbana-Champaign and Lawrence Berkeley National Laboratory’s National Energy Research Scientific Computing Center (NERSC).
About C3.ai, Inc.
C3 AI is the Enterprise AI application software company. C3 AI delivers a family of fully integrated products including the C3 AI Application Platform, an end-to-end platform for developing, deploying, and operating enterprise AI applications and C3 AI Applications, a portfolio of industry-specific SaaS enterprise AI applications that enable the digital transformation of organizations globally. Learn more at: www.c3.ai.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220324005202/en/
Contact information
C3.ai DTI Contact:
Kap Stann
Communications Manager, C3.ai DTI @ Berkeley
510-295-9685
kstann@berkeley.edu
C3 AI Public Relations:
Edelman
Lisa Kennedy
415-914-8336
pr@c3.ai
C3 AI Investor Relations
ir@c3.ai
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
